N-acetylcysteine
Small molecule targets MTOR, VWF via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ACETADOTE | — | 2024-11-26 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | MUCOMYST | — | 1985-01-31 – 2009-03-13 | fda.gov ↗ |
| Approved | US (FDA) | MUCOMYST | — | 1963-09-14 | fda.gov ↗ |
Trials 361 · started per year
Also used as a comparator or background therapy in 136 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT05798481 Background | Mar 2024 → Apr 2025 | hypertensive disorder | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 0 | NCT04987775 Comparator | Nov 2023 → Apr 2026 overdue | persian gulf syndrome | Nova Southeastern University | Recruiting | No outcome recorded |
| Phase 0 | NCT05927259 Comparator | Jan 2022 → May 2023 | organophosphate poisoning | Ain Shams University | Completed | No outcome recorded |
| Phase 0 | NCT03253328 Comparator | Mar 2017 → Aug 2021 | diabetes mellitus, limb ischemia, peripheral arterial disease | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT00609102 Comparator | Jul 2008 → Sep 2013 | type 2 diabetes mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT05908513 Comparator | Oct 2021 | atherosclerosis, diabetes mellitus, peripheral arterial disease | University of Missouri-Columbia | Withdrawn | No outcome recorded |
| Phase 1 | NCT04260516 Comparator | Jun → Dec 2019 | beta-thalassemia major | Beni-Suef University | Completed | No outcome recorded |
| Phase 1 | NCT03177395 Background | Jun 2017 → Aug 2018 | paracetamol poisoning | Egetis Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03154580 Comparator | May 2017 → Jun 2023 | substance abuse | Wayne State University | Completed | No outcome recorded |
| Phase 1 | NCT02493933 Comparator | Jul → Dec 2015 | infertility disorder | Kasr El Aini Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT02124941 Comparator | Feb 2014 → Aug 2022 | cocaine dependence | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT01251315 Comparator | Dec 2010 → Jun 2011 | — | Charles Drew University of Medicine and Science | Completed | No outcome recorded |
| Phase 1 | NCT01063205 Comparator | Mar 2010 → Jul 2011 | methamphetamine dependence, substance abuse | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01506765 Comparator | Aug 2003 → Dec 2004 | schizophrenia | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT06252441 Comparator | Mar 2024 → May 2025 | pancreatitis | Tanta University | Completed | No outcome recorded |
| Phase 1/2 | NCT04594733 Comparator | Dec 2021 → Aug 2022 | fibromyalgia | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1/2 | NCT04562597 Comparator | Jan 2021 → May 2022 | — | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1/2 | NCT04291209 Comparator | Feb 2020 → May 2024 | platinum-induced ototoxicity | Sunnybrook Health Sciences Centre | Unknown | No outcome recorded |
| Phase 1/2 | NCT02362425 Comparator | Feb 2015 → May 2018 | neuromuscular disease | National Institute of Nursing Research (NINR) | Completed | No outcome recorded |
| Phase 1/2 | NCT01187108 Comparator | Jun → Sep 2013 | chronic mountain sickness, polycythemia | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1/2 | NCT01470027 Comparator | Jan 2012 → Aug 2016 | Parkinson disease | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 1/2 | NCT00568087 Comparator | Dec 2007 → Aug 2009 | alcohol dependence | Minneapolis Veterans Affairs Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00611897 Comparator | Jan 2006 → Feb 2011 | cognitive disorder | Yale University | Completed | No outcome recorded |
| Phase 230 trials | ||||||
| Phase 2 | NCT07245095 Comparator | Sep 2025 → Nov 2026 expected | Helicobacter pylori infectious disease, gastric neoplasm, upper digestive tract disorder | Hospital General de Mexicali | Recruiting | No outcome recorded |
| Phase 2 | NCT06354712 Comparator | Apr 2024 → Mar 2025 overdue | mucositis | Mansoura University | Recruiting | No outcome recorded |
| Phase 2 | NCT06297369 Comparator | Feb 2024 → Feb 2025 | chemotherapy-induced neuropathy, cisplatin toxicity, platinum-induced ototoxicity | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT06095258 Comparator | Dec 2023 → Nov 2025 | long COVID-19 | Chinese University of Hong Kong | Unknown | No outcome recorded |
| Phase 2 | NCT05485558 Comparator | Sep 2022 → Jun 2024 | epilepsy | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT05517668 Background | Sep 2022 → Oct 2025 | drug-induced liver injury, liver failure, paracetamol poisoning | Richard Dart, MD, PhD | Terminated | No outcome recorded |
| Phase 2 | NCT00775476 Comparator | May 2022 → Mar 2027 expected | systemic lupus erythematosus | State University of New York - Upstate Medical University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05122559 Comparator | Feb 2022 → Feb 2027 expected | primary progressive multiple sclerosis, secondary progressive multiple sclerosis | Emmanuelle Waubant, MD PhD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04732000 Comparator | Jul 2021 → Mar 2023 | — | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT04864496 Comparator | Apr 2021 → Mar 2022 | retinitis pigmentosa | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT04419025 Comparator | Sep 2020 → May 2021 | COVID-19, severe acute respiratory syndrome | Cambridge Health Alliance | Completed | No outcome recorded |
| Phase 2 | NCT04440280 Comparator | Sep 2020 → Apr 2026 overdue | Fuchs' endothelial dystrophy | Massachusetts Eye and Ear Infirmary | Recruiting | No outcome recorded |
| Phase 2 | NCT04542161 Comparator | Sep 2020 → Apr 2027 expected | myalgic encephalomeyelitis/chronic fatigue syndrome | Weill Medical College of Cornell University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03636932 Comparator | Apr 2019 → Feb 2021 | chronic kidney disease | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 2 | NCT03510741 Comparator | Jan 2019 → Dec 2020 | schizoaffective disorder, schizophrenia, schizophreniform disorder | Pakistan Institute of Living and Learning | Completed | No outcome recorded |
| Phase 2 | NCT03306979 Comparator | Apr 2018 → Sep 2023 | cognitive impairment with or without cerebellar ataxia | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 2 | NCT02804594 Comparator | Oct 2016 → Jun 2018 | multiple sclerosis | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT02737358 Comparator | Aug 2016 → Aug 2019 | nicotine dependence | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT02294591 Comparator | Nov 2014 → Oct 2016 | bipolar disorder | Region Syddanmark | Completed | No outcome recorded |
| Phase 2 | NCT02080182 Comparator | Jan 2014 → Apr 2016 | acute pyelonephritis | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02760901 Comparator | Nov 2013 → Oct 2015 | cisplatin toxicity | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT01063348 Comparator | Sep 2012 → Jul 2015 | neurotic excoriation | University of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT01354132 Comparator | May 2011 → Aug 2014 | schizophrenia | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01005810 Comparator | Sep 2009 → Aug 2011 | cannabis dependence | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT00809094 Comparator | Nov 2008 → Feb 2011 | cystic fibrosis | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00627705 Comparator | Feb 2008 → Sep 2010 | autism | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00391911 Comparator | Nov 2006 → Dec 2010 | myopathy | Royal Alexandra Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00354770 Comparator | Jul 2006 → Sep 2008 | trichotillomania | University of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT00203099 Comparator | Dec 2004 → Aug 2006 | relapsing-remitting multiple sclerosis | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00003346 Background | Nov 1997 → Feb 2003 | cutaneous melanoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT02775734 Comparator | May 2016 → Mar 2017 | polycystic ovary syndrome | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT02088502 Comparator | Sep 2013 → Apr 2014 | — | Isfahan University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT00830193 Comparator | Aug 2002 → May 2005 | acute tubulointerstitial nephritis, critical illness polyneuropathy | Unity Health Toronto | Completed | No outcome recorded |
| Phase 322 trials | ||||||
| Phase 3 | NCT07464886 Comparator | Feb 2026 → Mar 2030 expected | mood disorder | University of Cincinnati | Recruiting | No outcome recorded |
| Phase 3 | NCT07380347 Comparator | Feb → Jul 2026 overdue | neonatal sepsis | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07157722 Comparator | Aug → Dec 2025 overdue | beta thalassemia | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07229456 Comparator | Oct 2024 → Oct 2025 overdue | — | Ain Shams University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06039566 Comparator | Nov 2023 → Nov 2026 expected | — | Medical University of South Carolina | Recruiting | No outcome recorded |
| Phase 3 | NCT03900988 Comparator | May 2023 → Oct 2025 | influenza | Chinese University of Hong Kong | Unknown | No outcome recorded |
| Phase 3 | NCT05906498 Comparator | Dec 2022 → Nov 2023 | psoriasis | Badr University | Unknown | No outcome recorded |
| Phase 3 | NCT04928495 Comparator | Jul 2021 → Apr 2022 | COVID-19 | Federal University of Ceará | Unknown | No outcome recorded |
| Phase 3 | NCT04792021 Comparator | Mar → Sep 2021 | COVID-19 | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT03755700 Comparator | Nov 2018 → Dec 2019 | acute coronary syndrome, coronary artery disorder | Rajaie Cardiovascular Medical and Research Center | Unknown | No outcome recorded |
| Phase 3 | NCT01675661 Comparator | Jan 2014 → Jul 2015 | cannabis dependence | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 3 | NCT01467466 Comparator | Oct 2013 → Sep 2017 | acute kidney injury, coronary artery disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 3 | NCT01993849 Comparator | Oct 2013 → Jun 2015 | nail disorder | Kevin Gray, MD | Completed | No outcome recorded |
| Phase 3 | NCT02124525 Comparator | Feb 2013 → Apr 2014 | disorder of defective peroxisome oxidative status, nicotine dependence | State University of Londrina | Unknown | No outcome recorded |
| Phase 3 | NCT01403506 Comparator | Apr 2011 → Apr 2012 | disease related to solid organ transplantation | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT01210456 Comparator | Oct 2009 → Oct 2014 | chronic kidney disease | Tokushukai Medical Group | Unknown | No outcome recorded |
| Phase 3 | NCT00650091 Comparator | Oct 2009 → Oct 2013 | idiopathic pulmonary fibrosis | Duke University | Completed | No outcome recorded |
| Phase 3 | NCT01098032 Comparator | Jan 2009 → Dec 2010 | chronic kidney disease | Clinica Mediterranea | Completed | No outcome recorded |
| Phase 3 | NCT00585559 Comparator | Apr 2007 → Oct 2023 | acquired aneurysmal subarachnoid hemorrhage, intracranial vasospasm | Vanderbilt University Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT00188630 Comparator | Jul 2003 → Feb 2007 | acute kidney injury, heart disorder | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 3 | NCT00962442 Comparator | Sep 2000 → Jan 2006 | alcoholic hepatitis | Erasme University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00248625 Comparator | Jan 2000 → Sep 2009 | acute liver failure, hepatic encephalopathy | University of Pittsburgh | Completed | No outcome recorded |
| Phase 425 trials | ||||||
| Phase 4 | NCT07301294 Comparator | Jan → Jun 2026 overdue | — | Menoufia University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05936528 Comparator | Sep 2025 → Jul 2026 | — | Mansoura University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT06486805 Comparator | Jun → Nov 2024 | disorder of defective peroxisome oxidative status, liver disorder | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05944458 Comparator | Aug 2023 → Jun 2025 | thrombocytopenia | Helwan University | Completed | No outcome recorded |
| Phase 4 | NCT06202911 Comparator | Jan 2023 → Mar 2024 | necrotizing enterocolitis | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT04766450 Comparator | Dec 2021 → Nov 2022 | diabetic neuropathy | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT04509258 Comparator | Oct 2020 → Oct 2021 | — | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT04209803 Comparator | Dec 2018 → Sep 2020 | androgenetic alopecia | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 4 | NCT03354572 Comparator | Oct 2017 → Oct 2018 | — | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03708458 Comparator | Apr 2017 → Dec 2018 | pancreatitis | Grigore T. Popa University of Medicine and Pharmacy | Unknown | No outcome recorded |
| Phase 4 | NCT03589495 Comparator | Jul 2015 → Oct 2016 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT02579772 Comparator | Jul 2015 → May 2016 | chronic obstructive pulmonary disease | Queen's University | Completed | No outcome recorded |
| Phase 4 | NCT02357303 Comparator | Apr → Dec 2015 | stomach disorder | Portuguese Oncology Institute, Coimbra | Completed | No outcome recorded |
| Phase 4 | NCT01866800 Comparator | Jun 2013 → Apr 2019 | aortic valve disorder | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01501110 Comparator | Nov 2011 → Jul 2013 | acute myocardial infarction, euthyroid sick syndrome, ischemic disease | Federal University of Rio Grande do Sul | Completed | No outcome recorded |
| Phase 4 | NCT02168387 Comparator | Dec 2010 → May 2012 | lung disorder | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT01136239 Comparator | Feb 2010 → Feb 2012 | chronic obstructive pulmonary disease | Kwong Wah Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00969904 Comparator | Mar 2009 → Jan 2011 | chronic obstructive pulmonary disease | University Hospital, Antwerp | Completed | No outcome recorded |
| Phase 4 | NCT00896025 Comparator | Dec 2008 → Oct 2015 | acute liver failure | University of Texas Southwestern Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT00716001 Comparator | Jul 2008 → Jun 2009 | chronic renal failure syndrome | Osaka General Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00558142 Comparator | Feb 2008 → Jan 2015 | — | University of Edinburgh | Completed | No outcome recorded |
| Phase 4 | NCT00525551 Comparator | Sep 2007 → Apr 2013 | otosclerosis | Karolinska University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00939913 Comparator | Jan 2007 → May 2010 | — | Ochsner Health System | Unknown | No outcome recorded |
| Phase 4 | NCT00512265 Comparator | Jan 2006 → Jul 2008 | lung disorder | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT01021163 Comparator | — | arterial occlusion | Yonsei University | Completed | No outcome recorded |
| Phase not applicable33 trials | ||||||
| — | NCT07293884 Comparator | Dec 2025 → Mar 2026 overdue | bronchiectasis | Assiut University | Not yet recruiting | No outcome recorded |
| — | NCT06377410 Comparator | May 2024 → Nov 2026 expected | chronic obstructive pulmonary disease | National University of Malaysia | Recruiting | No outcome recorded |
| — | NCT03177889 Background | Dec 2021 → Aug 2023 | bronchiectasis | Guangzhou Institute of Respiratory Disease | Unknown | No outcome recorded |
| — | NCT05089981 Comparator | Nov 2021 → Mar 2023 | liver disorder | Aga Khan University | Unknown | No outcome recorded |
| — | NCT05804123 Background | Oct 2021 → Apr 2024 | respiratory tract infectious disorder | Anabio R&D | Completed | No outcome recorded |
| — | NCT07470242 Comparator | Oct 2021 → Mar 2023 | chronic rhinosinusitis | Pusan National University Hospital | Completed | No outcome recorded |
| — | NCT04793646 Comparator | Apr 2021 → Dec 2024 | Sjogren syndrome | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| — | NCT05264584 Background | Dec 2020 → Sep 2021 | chronic kidney disease | Ain Shams University | Completed | No outcome recorded |
| — | NCT04641455 Comparator | Dec 2020 → May 2021 | gastric cancer | Vitkovice Hospital | Unknown | No outcome recorded |
| — | NCT04904952 Comparator | Mar 2020 → Jan 2022 | obsessive-compulsive disorder | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| — | NCT02718079 Background | Dec 2016 → Oct 2018 | acute liver failure | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT02999958 Comparator | Dec 2016 → May 2018 | — | Vitrolife | Completed | No outcome recorded |
| — | NCT02971878 Comparator | Nov 2016 → Feb 2018 | — | Fertilitetscentrum AB | Completed | No outcome recorded |
| — | NCT02159196 Comparator | Jul 2014 → Mar 2017 | respiratory failure | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| — | NCT02088216 Comparator | Apr 2014 → Dec 2017 | bronchiectasis | Qilu Hospital of Shandong University | Completed | No outcome recorded |
| — | NCT01891292 Comparator | Jul 2013 → Aug 2014 | proteinuria, sickle cell disease | The University of The West Indies | Unknown | No outcome recorded |
| — | NCT01739790 Comparator | Jan 2013 → Dec 2015 | chronic bronchitis | University of Minnesota | Terminated | No outcome recorded |
| — | NCT01727492 Comparator | Nov 2012 → ? | noise induced hearing loss, tinnitus | University Hospital, Antwerp | Unknown | No outcome recorded |
| — | NCT01599884 Comparator | Jun 2012 → May 2013 | chronic bronchitis | Center for Veterans Research and Education | Unknown | No outcome recorded |
| — | NCT01386645 Comparator | Jul 2011 → Aug 2019 | disorder of defective peroxisome oxidative status, glucose intolerance, prediabetes syndrome | Seattle Institute for Biomedical and Clinical Research | Completed | No outcome recorded |
| — | NCT01160627 Comparator | Apr 2010 → Mar 2013 | acute tubulointerstitial nephritis | Odense University Hospital | Completed | No outcome recorded |
| — | NCT00893724 Comparator | Jun 2009 → Aug 2011 | diabetic macular edema, wet macular degeneration | Mid-Atlantic Retina Consultations, Inc. | Unknown | No outcome recorded |
| — | NCT01597765 Background | Jun 2009 → Jun 2011 | thalassemia | Mahidol University | Completed | No outcome recorded |
| — | NCT00889538 Comparator | Apr 2009 → Sep 2012 | autism, disruptive behavior disorder | University of Louisville | Completed | No outcome recorded |
| — | NCT01037465 Comparator | Sep 2008 → Dec 2015 | cardiovascular disorder | Boston University | Completed | No outcome recorded |
| — | NCT00787813 Comparator | Jun → Oct 2008 | cervical incompetence | Assiut University | Completed | No outcome recorded |
| — | NCT00637624 Comparator | Mar 2008 → Jul 2017 | mesothelioma, non-small cell lung carcinoma, small cell lung carcinoma | Rijnstate Hospital | Terminated | No outcome recorded |
| — | NCT01907061 Comparator | Jul 2007 → Jul 2014 | acute kidney injury | Baylor Research Institute | Completed | No outcome recorded |
| — | NCT00570388 Comparator | Mar 2007 → Sep 2008 | alcohol dependence | Institute of Addiction Medicine | Unknown | No outcome recorded |
| — | NCT00579995 Comparator | May 2005 → Apr 2010 | — | University of Nebraska | Terminated | No outcome recorded |
| — | NCT01612013 Comparator | May 2005 → May 2009 | acute kidney injury | Federal University of São Paulo | Completed | No outcome recorded |
| — | NCT00994305 Comparator | Apr 2005 → Jun 2008 | — | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| — | NCT00851708 Comparator | — | — | University of Sao Paulo | Completed | No outcome recorded |
Evidence & citations 34 cited values
Every value below carries the sentence it was read from. 546 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N acetyl cysteine | “The investigators are going to observe if add-on of n-acetylcysteine (NAC) 1200 or 2400 mg/d during tapering of antipsychotics in patients with remitted psychosis can help to...” NCT06546475 ↗484“The randomized placebo-controlled IFIGENIA-trial demonstrated that therapy with high-dose N-acetylcysteine (NAC) given for one year, added to prednisone and azathioprine,...” PMID 19860915 ↗ Oct 2009 “Patients with an estimated glomerular filtration rate ≤30 mL · min(-1) · 1.73 m(-2) and/or a risk score ≥11 were randomly assigned to sodium bicarbonate solution and...” PMID 21844075 ↗ Aug 2011 “The objective of this study is to assess the efficacy of sodium bicarbonate compared with sodium chloride and oral N-acetylcysteine (NAC ) pretreatment for prevention of...” NCT00353340 ↗ “Previous studies found N-acetylcysteine (NAC), a slimy solvent ingredient in human body, by means of extra-cellular glutamate exchange mechanism, not only maintain glutamate...” NCT01047956 ↗ “We conducted a study to determine whether N-Acetyl-cysteine (NAC) protected men against noise-induced temporary threshold shift (TTS), and whether subgroups with genetic...” PMID 20638463 ↗ Jul 2010 “This study compares N-acetylcysteine (mucomyst) and sodium chloride to determine their efficacy in the prevention of pulmonary mucus obstruction and retention in intubated...” NCT00131521 ↗ “This study proposes a randomized, double-blind, placebo-controlled crossover trial to assess the effects of a prophylactic combination of N-acetylcysteine (600 mg) and...” PMID 24708640 ↗ Apr 2014 “Preclinical studies have demonstrated that N-acetylcysteine stabilizes levels of glutamate and glutathione and reduces alcohol-seeking behaviors, indicating it as a potential...” PMID 41128676 ↗ Dec 2025 “Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular...” NCT06039280 ↗ “N-acetyl cysteine (NAC) has a well-established safety profile, its remarkable antioxidant and anti-inflammatory capacity is the biochemical basis used to treat several diseases...” NCT07229456 ↗ “Effect of N-acetylcysteine Versus Calcium Hydroxide Used as an Intracanal Medicament on the Intensity of Postoperative Pain, Bacterial Load Reduction and Levels of MMP -9 in...” NCT05666089 ↗ “BACKGROUND: N-acetylcysteine (NAC) or sodium bicarbonate (NaHCO3), singly or combined, inconsistently prevent patients exposed to radiographic contrast media from developing...” PMID 25254489 ↗ Sep 2014 “N-acetylcysteine (NAC) is a small molecule containing a thiol (sulfhydryl-containing) group, which has antioxidant properties and is freely filterable, thus making it readily...” NCT06486805 ↗ “Using block-stratified randomization, 156 adult patients undergoing stapedotomy were assigned to intravenous N-Acetylcysteine (150 mg/kg body weight) or matching placebo (1:1...” PMID 25763866 ↗ Mar 2015 “The antioxidants are ascorbic acid (vitamin C) 3 grams intravenously preoperatively and N-acetylcysteine 100 milligrams/kilogram body weight intravenous infusion for 4 hours,...” NCT03494387 ↗ “acetaminophen (APAP), N-acetylcysteine (NAC) and APAP in combination with NAC will inhibit lipid peroxidation in aneurysmal subarachnoid hemorrhage (aSAH), utilizing F2-IsoPs...” NCT00585559 ↗ “N-acetylcysteine (NAC), an FDA-approved medication and over-the-counter supplement, has shown promise in animal studies and randomized controlled trials (RCTs) in reducing...” NCT04627922 ↗ “The purpose of this study is to evaluate the effects of the amino acid supplement N-Acetylcysteine versus placebo on working memory and other cognitive functions in persons...” NCT01232790 ↗ “This study evaluated the efficacy, safety, and cost-effectiveness of oral N-acetylcysteine (NAC) in preventing AmB-d nephrotoxicity and promoting renal recovery in Egyptian...” PMID 40342610 ↗ May 2025 “This daily intervention over 3 months combines 4 g L-serine, 14 g L-glutamine, 3 g L-arginine, 2.5 g N-acetylcysteine, 5.75 g L-citrulline, 1 g vitamin C, and 5 g creatine to...” NCT06967428 ↗ “N-acetyl cysteine (NAC) is a potential pharmacotherapy for alcohol use disorder (AUD), but it is not known whether it modulates neural activation to alcohol cues or intrinsic...” PMID 39102049 ↗ Aug 2024 “Anti-oxidants such as N-acetylcysteine (NAc), Vitamin C (ascorbic acid) (VitC) and Vitamin E (alpha-tocopherol) (VitE) are potent FRS 'scavengers', which means they could be...” NCT02629536 ↗ “N-acetylcysteine (NAC) is a thiolic amino acid that has been reported to scavenge free radicals, replenish reduced glutathione (GSH), prevent its depletion, and inhibit lipid...” NCT06297369 ↗ “BACKGROUND: Although high-dose N-acetylcysteine (NAC) has been suggested to reduce COPD exacerbations, it is unclear which category of patients with COPD would benefit most...” PMID 24833327 ↗ Sep 2014 “We hypothesized that oral supplementation with N-acetylcysteine, a precursor to the antioxidant glutathione, would improve cognitive outcomes among individuals with mild...” PMID 42045982 ↗ Apr 2026 “N-acetylcysteine (NAC) has been shown to improve negative symptoms of schizophrenia, however, results from trials of other compounds targeting NMDA neurotransmission have been mixed.” PMID 39144112 ↗ Feb 2024 “GlyNAC 200 mg/kg/day (100mg glycine and 100mg N-acetyl-cysteine) will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively.” NCT06083480 ↗ “Pharmacokinetic data suggests that the intravenous form of n-acetylcysteine (NAC) may be more effective than the oral formulation in preventing contrast induced nephropathy (CIN).” PMID 21542122 ↗ Nov 2011 “The purpose of this study is to evaluate the efficacy of N-acetylcysteine (NAC) in preventing cisplatin-induced ototoxicity in patients receiving cisplatin-based chemotherapy.” NCT07364747 ↗ “The goal of this clinical trial is to evaluate if N-acetylcysteine (NAC) works to prevent post-tuberculosis lung disease (PTLD) in patients with severe pulmonary impairment.” NCT06909799 ↗ “Treatment arm will include dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside + standard therapy (hydroxychloroquine).” NCT04573153 ↗ “Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture.” NCT04330326 ↗ “OBJECTIVE: To examine the efficacy of N-acetylcysteine (NAC) for the treatment of pediatric trichotillomania (TTM) in a double-blind, placebo-controlled, add-on study.” PMID 23452680 ↗ Mar 2013 “Animal studies have shown that INH-RIF-induced oxidative injury can be prevented by supporting the cellular antioxidant defense mechanism by N-acetylcysteine (NAC).” NCT02889757 ↗ “The aim of the study is to evaluate the effect of N-acetyl cysteine (NAC) on pregnancy outcome in women undergoing cervical cerclage for cervical insufficiency.” NCT00787813 ↗ “This study examined the addition of N-acetylcysteine to imaginal desensitization in adults with co-occurring nicotine dependence and pathological gambling.” PMID 24345329 ↗ Jan 2014 “To evaluate the impact of N-acetyl-cysteine (NAC) on amputation stump perfusion and healing in patients with critical limb-threatening ischemia (CLTI).” PMID 35129469 ↗ Jan 2022 “A Phase 1 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa” NCT03999021 ↗ “Simethicone and N-acetylcysteine (NAC) are commonly used to improve mucosal visibility, but the optimal timing of administration remains uncertain.” PMID 41960652 ↗ Apr 2026 “N-acetylcysteine (NAC) is an amino acid derivative, is a health supplement, and has neuroprotective effects that target the glutamatergic system.” NCT04904952 ↗ “N-acetylcysteine (NAC) is an antioxidant commonly used in the treatment of acetaminophen overdose, and has well documented mucolytic properties.” NCT00956748 ↗ “N-acetylcysteine (NAC) has shown beneficial antimicrobial, antioxidant, and immunomodulatory effects in preclinical tuberculosis models.” PMID 39189858 ↗ Aug 2024 “with mucolytic solution (100 mL water + 400 mg N-acetylcysteine + 20 mg simethicone), without the solution , and with 100 mL pure water.” PMID 34158672 ↗ Jun 2021 “This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis.” NCT03720483 ↗ “N-acetylcysteine (NAC) acts as an antioxidant both directly as a glutathione substitute and indirectly as a precursor for glutathione.” NCT07080190 ↗ “We previously reduced MRI in rats through a combined antioxidant therapy (CAT) of ascorbic acid, N-acetylcysteine, and deferoxamine.” PMID 38973337 ↗ Jul 2024 “concomitant use of antioxidants as N-acetylcysteine, alpha lipoic acid in preventing or attenuating colistin induced nephrotoxicity” NCT06650384 ↗ “We randomly assigned 174 patients to receive prednisolone plus N-acetylcysteine (85 patients) or only prednisolone (89 patients).” PMID 22070475 ↗ Nov 2011 “N-acetyl-cysteine (NAC), a glutathione precursor, was administered to patients in a randomized, double-blind, crossover protocol” PMID 22383949 ↗ Feb 2012 “N-Acetylcysteine (NAC), a potent anti-oxidant, may prevent IH by improving tissue oxygen delivery and improving hepatic hypoxia.” PMID 32048131 ↗ Feb 2020 “In this arm the participants will receive 600 mg N-acetyl cysteine dissolved in 100 ml water 10-30 minutes before the procedure” NCT05951712 ↗ “N-acetylcysteine (NAC), alternatively referred to as N-acetyl-L-cysteine, is an acetylated version of the amino acid L-cysteine” NCT07634991 ↗ “N-acetyl cysteine (NAC) is an antioxidant, widely used as mucolytic agent or antidote of acetaminophen overdose hepatotoxicity.” NCT04756622 ↗ “Karapinar et al N-acetylcysteine (NAC) has been proposed as a potential alternative therapeutic agent in root canal treatment.” NCT05985759 ↗ “The combination drink containing N-acetyl cysteine and simethicone help to disperse bubbles and mucus present in the stomach.” NCT05801055 ↗ “This is a 12-week randomized, placebo-controlled trial of N-acetylcysteine for cannabis use disorder (CUD) in youth (N=192).” NCT03055377 ↗ “oral mucolytics [ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid]” NCT03177889 ↗ “The ACTS Trial: N-acetylcysteine (NAC) and Night-splinting as a Non-operative Treatment for Carpal Tunnel Syndrome” NCT04460521 ↗ “N-acetylcysteine Plus Transcutaneous Vagus Nerve Stimulation in Infants of Diabetic Mothers Who Fail Oral Feeding” NCT04632069 ↗ “The intravenous (IV) N-acetylcysteine (NAC) regimen introduced in the 1970s has continued effectively unchanged.” PMID 23556549 ↗ Apr 2013 “N-acetylcysteine (NAC) is a well-tolerated, inexpensive treatment with antioxidant and anti-fibrotic properties.” PMID 36514019 ↗ Dec 2022 “ALTH12-1:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 1.0g N-acetylcysteine” NCT01020708 ↗ “N- acetylcysteine group will receive N-acetylcysteine 900mg once daily with antituberculous drugs for 14 days” NCT07058090 ↗ “It is not known whether addition of N-acetyl cysteine (NAC) to G-CSF could further increase survival time.” PMID 29391265 ↗ Jan 2018 “Dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside.” NCT04044131 ↗ “N-Acetylcysteine (NAC) has shown promise as a putative neurotherapeutic for traumatic brain injury (TBI).” PMID 37596428 ↗ Aug 2023 “The Role of N-acetylcysteine as a Novel Adjuvant Treatment in Acute Organophosphorus Pesticide Poisoning” NCT05927259 ↗ “vapor with diclofenac sodium, menthol, methyl salicylate and N-acetyl cysteine may augment this effect.” NCT04900129 ↗ “N-acetylcysteine (NAC), a glutathione precursor and potent antioxidant, is known as a liver protector.” NCT06039280 ↗ “N-acetylcysteine (NAC) is commonly prescribed for such patients but with uncertain clinical benefits.” PMID 27143871 ↗ Apr 2016 “N-acetylcysteine (NAC) reduces oxidative damage and increases cone function/survival in RP models.” PMID 31805012 ↗ Mar 2020 “Since N-acetyl cysteine (NAC) has been proven to have antioxidant and anti-inflammatory properties” NCT05576428 ↗ “4.7% N-acetylcysteine, 2% Hydroquinone and 0.1 % triamcinolone acetate twice daily for 8 weeks” NCT07508098 ↗ “N-Acetylcysteine (NAC) is on the market since 1968 and is an over the counter available agent” NCT03354572 ↗ “Injection of a 10% solution of N-acetylcysteine through transtympanic injection in both ears” NCT04226456 ↗ “Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg)” NCT00889538 ↗ “oral adminstration of clomiphene citrate plus metformin plus N acetyl cysteine or chromium” NCT04170439 ↗ “N-Acetyl Cysteine Helps Pulp Stem Cells Differentiate During Endodontic Revascularization” NCT03451435 ↗ “N-acetylcysteine (NAC), a sulfhydryl group-containing compound with mucolytic properties” NCT07340944 ↗ “Among these N-acetylcysteine, an antioxidant agent that has shown otoprotective effect.” NCT03400709 ↗ “The procedure involved would be the administration of N-acetylcysteine via nebulization” NCT03346681 ↗ “N-acetylcysteine (NAC) may mitigate hepatotoxicity, especially among slow acetylators.” NCT06484530 ↗ “Intravenous N-acetyl cysteine bolus and infusion as described in the experimental arm.” NCT04023266 ↗ “standard of care + minocycline + N-acetylcysteine (NAC) relative to standard of care” NCT04594733 ↗ “N-acetylcysteine (NAC) has been widely used as an antioxidant in vivo and in vitro.” NCT04209803 ↗ “N-acetyl cysteine (NAC) 600 mg will be administered orally once daily for 12 weeks.” NCT07157722 ↗ “Zoenasa Rectal Gel (4.0g mesalamine \[5-ASA\], 1.0g N-acetylcysteine \[NAC\]; 60ml)” NCT01586533 ↗ “N-acetyl cysteine (NAC) is a drug that is metabolized by the body to form cysteine” NCT00218491 ↗ “Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention” NCT01878344 ↗ “INTRODUCTION: N -acetylcysteine (NAC) may be neuroprotective by minimizing” PMID 35393384 ↗ Apr 2022 “N-acetyl cysteine (NAC) is a widely used drug in human clinical practices.” NCT07323719 ↗ “Intervention Name: N-acetylcysteine (NAC) Other Intervention Names: NAC” NCT06482034 ↗ “over-the counter study anti-oxidant drug called N-acetylcysteine (NAC)” NCT01537926 ↗ “N-acetyl-cysteine + Clomiphene citrate + Laparoscopic ovarian drilling” NCT02775734 ↗ “using N-acetylcysteine (NAC), a well-tolerated nutritional supplement” NCT04278898 ↗ “N-acetyl Cysteine and Patients with Non-alcoholic Fatty Liver Disease” NCT05589584 ↗ “N-acetylcysteine (NAC) is a modified form of the amino acid cysteine” NCT03900988 ↗ “N-acetylcysteine (NAC) may have an interest in the treatment of ICD.” NCT03146130 ↗ “N-acetylcysteine, is a drug that has been long used as a mucolytic.” NCT04405193 ↗ “intravenous N-acetylcysteine (NAC) can improve bile flow after KP.” NCT03499249 ↗ “percutaneous administration of bromelain + N-acetylcysteine (NAC)” NCT04982146 ↗ “high dose of N-acetylcysteine (NAC) plus preprocedural hydration” PMID 41701447 ↗ Feb 2026 “N-acetylcysteine (NAC), a well-tolerated nutritional supplement” NCT05664789 ↗ “N-acetylcysteine. Tablets, 600 mg. 600 mg dose every 12 hours.” NCT04570254 ↗ “plus oral N-acetylcysteine (NAC) 1200 mg (600mg twice daily)” NCT03281226 ↗ “aerosolized N-Acetylcysteine (NAC) into airway mucus plugs” NCT06152653 ↗ “N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet” NCT02629536 ↗ “with a dietary supplement called N-Acetyl Cysteine (NAC).” NCT02794389 ↗ “600 mg of N-acetylcysteine (3 tablets of 200 mg ACC long)” NCT04641455 ↗ “N-acetyl cysteine (NAC) is synthetic cysteine amino acid” NCT05906498 ↗ “N acetyl-cysteine(NAC) have been tried for this purpose.” NCT05801055 ↗ “Group A and Group B will receive N-Acetylcysteine (NAC).” NCT05340504 ↗ “Topical 5% Minoxidil and N-Acetyl-Cysteine 600 mg orally” NCT04209803 ↗ “inhaled N-Acetylcysteine (NAC) to improve lung function” NCT00996424 ↗ “N-acetylcysteine (NAC), an effective mucolytic agent” NCT07293884 ↗ “100 mg/kg n acetyl cysteine dissolved in dextrose5%” NCT03589495 ↗ “paclitaxel + N-Acetylcysteine orally short course” NCT05539053 ↗ “N-acetyl-cysteine (NAC), a glutathione precursor” NCT05485558 ↗ “N-acetylcysteine start day +1 through day +28” NCT02171104 ↗ “three doses of intravenous N-Acetyl cysteine” NCT05089981 ↗ “N-acetylcysteine (NAC) as an antioxidant and” PMID 31381364 ↗ Aug 2019 “N-Acetyl Cysteine, a glutathione precursor” NCT01251315 ↗ “N-acetyl-cysteine (NAC) : 2400 mg per day” NCT05796401 ↗ “N-acetylcysteine or CC plus l-carnitine.” PMID 31273783 ↗ Jul 2019 “Dietary Supplement: N-acetyl-cysteine” NCT01587001 ↗ “N-acetylcysteine (NAC) treatment” NCT04542161 ↗ “Generic name: N-acetylcysteine.” NCT05944458 ↗ “Saline and N-acetylcysteine” NCT01866800 ↗ “Drug: N acetyl cysteine” NCT06297369 ↗ “Drug: N-Acetyl cysteine” NCT04460521 ↗ “Drug: N-acetyl cysteine” NCT04300920 ↗ “Drug: N-acetyl cysteine” NCT06482034 ↗ “Drug: N-acetyl cysteine” NCT03055377 ↗ “Drug: N acetyl cysteine” NCT05944458 ↗ “N-Acetyl Cysteine (NAC)” NCT03063021 ↗ “N-acetylcysteine 600 mg” NCT03056014 ↗ “N-Acetylcysteine (NAC)” NCT00780962 ↗ “N-Acetylcysteine (NAC)” NCT07227649 ↗ “n-acetylcysteine” NCT00609102 ↗ |
| Known as | ACC | “N-acetylcysteine (ACC) 1200 mg In the 8-weeks run-in period angiotensin converting enzyme inhibitors and/or angiotensin II subtype 1 receptor antagonists were administered to...” NCT00572663 ↗1“The antioxidant acetylcysteine (ACC) was effective in patients with impaired renal function in at least six studies, but it was not preventive in at least 21 trials and two...” NCT00492518 ↗ |
| Known as | ACC long | “600 mg of N-acetylcysteine (3 tablets of 200 mg ACC long)” NCT04641455 ↗ |
| Known as | ACC-600 | “Generic name: N-acetyl cysteine. Brand: ACC-600 (Acetylcysteine). Strength: 600mg per capsule. Form: capsule Route: oral Frequency: 2x capsules twice per day = total 4...” NCT05408247 ↗ |
| Known as | Acetadote | “N-acetylcysteine (also known as Acetadote), an antioxidant medication” NCT00374088 ↗ |
| Known as | Acetine | “N-Acetylcysteine (NAC)(Acetine, 1200mg/day) group and placebo one.” NCT00552786 ↗ |
| Known as | Acetylcysteine | “Acetylcysteine (Flucistein 100 mg/ml, Neo Química, Brazil) was given via IV bolus at a rate of 150 mg/kg in 500 ml dextrose 5% over 60 min immediately before contrast exposure...” NCT01612013 ↗54“Generic name: N-acetyl cysteine. Brand: ACC-600 (Acetylcysteine). Strength: 600mg per capsule. Form: capsule Route: oral Frequency: 2x capsules twice per day = total 4...” NCT05408247 ↗ “Subgroup B1 will receive standard antioxidant drug (Acetyl cysteine 600 mg / 12 hr) orally to be compared with lactoferrin A1 subgroup.” NCT05936528 ↗ “The procedure involved would be the administration of N-acetylcysteine via nebulization” NCT03346681 ↗ “Clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle.” NCT02822287 ↗ “BromAc is a product that combines two existing products (Bromelain and Acetylcysteine)” NCT05220605 ↗ “effect of Acetyl cysteine compared to normal saline” NCT00996424 ↗ “acetylcysteine solution; oral 20% (200 mg/mL)” NCT02723669 ↗ “acetylcysteine” NCT01118663 ↗ |
| Known as | Acteylcysteine | “Drug: Acteylcysteine” NCT02889757 ↗ |
| Known as | AR10 | “AR10 (acetylcysteine effervescent tablets for oral solution” NCT02723669 ↗ |
| Known as | Flucistein | “Acetylcysteine (Flucistein 100 mg/ml, Neo Química, Brazil) was given via IV bolus at a rate of 150 mg/kg in 500 ml dextrose 5% over 60 min immediately before contrast exposure...” NCT01612013 ↗ |
| Known as | Fluimucil | “cough medicine (such as codeine), bronchodilators (such as ventolin), expectorants (such as fluimucil) and so on are used to treat cough, shortness of breath, or other...” NCT06095258 ↗ |
| Known as | fluimucil 100mg/ml | “3 mL-solution of acetylcysteine (fluimucil 100mg/ml)” NCT02159196 ↗ |
| Known as | Flumucil | “NAC (N-Acetylcysteine Tablets, brand name: Flumucil) has a drug specification of 600 mg per tablet.” NCT06956157 ↗ |
| Known as | Mucomyst | “This study compares N-acetylcysteine (mucomyst) and sodium chloride to determine their efficacy in the prevention of pulmonary mucus obstruction and retention in intubated...” NCT00131521 ↗4“The study will look at the effect of 30 days of treatment of 15 diabetics with proteinuria with N-acetylcysteine ( Mucomyst ) at a dose of 1 gm twice a day by mouth.” NCT00493727 ↗ “The study will examine the effects of treatment with N-acetylcysteine ( Mucomyst ) 1 gm twice a day for 30 dyas in 15 patients with hepatitis C.” NCT00493610 ↗ “The purpose of this study is to investigate the exact role of Acetylcysteine (Mucomyst) in altering creatinine clearance.” NCT00396396 ↗ “Acetylcysteine (Mucomyst) Nasal Irrigation” NCT07470242 ↗ |
| Known as | multivitamins with minerals | “Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion.” NCT00570388 ↗ |
| Known as | N-acetyl cysteine (NAC) | “N-acetyl cysteine (NAC)” NCT03253328 ↗ |
| Known as | N-acetyl-L-cysteine | “This is a prospective, single-arm trial designed to investigate whether atorvastatin combined with N-acetyl-L-cysteine (NAC) plus romiplostim can induce a sustained response...” NCT07662525 ↗19“For decades N-acetyl-L-cysteine (NAC) has been used for its mucolytic properties orally in different respiratory diseases like chronic obstructive pulmonary disease (COPD),...” NCT07409727 ↗ “The purpose of this study is to examine the effectiveness of using a combination of a drug, rifaximin and a dietary supplement, N-acetyl-L-cysteine (NAC), to treat patients...” NCT06727422 ↗ “This is a pilot study investigating the effect of an antioxidant, N-Acetyl-L-Cysteine (NAC), on inflammation and oxidative stress in sarcoidosis.” NCT01587001 ↗ “This study will test whether treatment with N-acetyl-L-cysteine (NAC) is safe and decreases pain in patients with chronic neuropathic pain.” NCT01840345 ↗ “N-acetylcysteine (NAC), alternatively referred to as N-acetyl-L-cysteine, is an acetylated version of the amino acid L-cysteine” NCT07634991 ↗ “The Efficacy and Safety of N-acetyl-L-cysteine (NAC) as Adjuvant Therapy in Acute on Chronic Liver Failure (ACLF)” NCT05089981 ↗ “N-acetyl-L-cysteine (NAC)” NCT02999958 ↗ “N-acetyl-L-Cysteine” NCT01241513 ↗ |
| Known as | N-acetyl-L-cysteine (NAC) | “N-acetyl-L-cysteine (NAC)” NCT02999958 ↗ |
| Known as | N-AcetylCystein | “Prophylactic controlled hydration with saline (0.9%) plus N-acetylcystein (NAC; 6 g in total).” NCT01098032 ↗1“N-AcetylCystein (NAC) is a scavenger of reactive oxygen species” NCT03440268 ↗ |
| Known as | N-acetylcysteine 200 mg brand name Mysoven | “N-acetylcysteine 200 mg brand name Mysoven” NCT01597765 ↗ |
| Known as | N-AcetylCysteyn | “N-AcetylCysteyn (NAC) for prevention of AKI” NCT03440268 ↗ |
| Known as | N-Acetyle cystein | “N-Acetyle cystein (NAC) has an optimal thiol redox state” NCT05089981 ↗ |
| Known as | N-acetyle cysteine | “Evaluation of gastric visibility following the combination drink of N-acetyle cysteine and simethocone” NCT05801055 ↗ |
| Known as | NAC | “The investigators are going to observe if add-on of n-acetylcysteine (NAC) 1200 or 2400 mg/d during tapering of antipsychotics in patients with remitted psychosis can help to...” NCT06546475 ↗229“Other drugs that can contribute to improve the situation of patients with this entity is N-acetylcysteine (NAC), however, in the different studies contradictory data are...” NCT05294744 ↗ “The randomized placebo-controlled IFIGENIA-trial demonstrated that therapy with high-dose N-acetylcysteine (NAC) given for one year, added to prednisone and azathioprine,...” PMID 19860915 ↗ Oct 2009 “This is a prospective, single-arm trial designed to investigate whether atorvastatin combined with N-acetyl-L-cysteine (NAC) plus romiplostim can induce a sustained response...” NCT07662525 ↗ “The study intends to test the hypothesis that combined oral supplementation of the antioxidants N-acetylcysteine (NAC) and milk thistle flavonolignan silibin (as...” NCT01265563 ↗ “Participants in this group received N-Acetylcysteine (NAC) at a dose of 140 mg/kg orally or via a nasogastric tube every 4 hours for the first 16 hours, followed by the same...” NCT06872372 ↗ “The purpose of this study is to demonstrate the feasibility of a 9-week, randomized trial of N-acetylcysteine (NAC) compared to placebo in 14 children (age 5 to 12 years) with...” NCT03008889 ↗ “The aim of this study was to investigate the influence of perioperative N-acetylcysteine (NAC) administration, a known antioxidant, on the incidence of acute kidney injury...” PMID 25384603 ↗ Feb 2015 “The objective of this study is to assess the efficacy of sodium bicarbonate compared with sodium chloride and oral N-acetylcysteine (NAC ) pretreatment for prevention of...” NCT00353340 ↗ “Previous studies found N-acetylcysteine (NAC), a slimy solvent ingredient in human body, by means of extra-cellular glutamate exchange mechanism, not only maintain glutamate...” NCT01047956 ↗ “The primary objective of this study is to evaluate the impact of N-acetylcysteine (NAC) 1200 mg versus matched placebo (PBO) twice daily, added to contingency management (CM),...” NCT01675661 ↗ “A randomized, double-blind, parallel-arm, phase II, explorative study investigating the efficacy and safety of orally administered N-Acetylcysteine (NAC) versus placebo in...” NCT05736887 ↗ “A Pilot, Multicenter, Open-label, One-group Study to Explore the Efficacy, Tolerability and Safety of the Combination of Glatiramer Acetate (GA) and N-Acetylcysteine (NAC) in...” NCT00203099 ↗ “For decades N-acetyl-L-cysteine (NAC) has been used for its mucolytic properties orally in different respiratory diseases like chronic obstructive pulmonary disease (COPD),...” NCT07409727 ↗ “This is a randomized, double-blinded, placebo-controlled trial to evaluate fenoldopam and N-acetylcysteine (NAC) individually, and together, as renal protective agents for...” NCT00122018 ↗ “In a recent phase 1 randomized clinical trial (RCT), it was revealed that oral N-acetylcysteine (NAC) was safe and well-tolerated in patients with moderately advanced RP and...” NCT04864496 ↗ “The purpose of this study is to examine the effectiveness of using a combination of a drug, rifaximin and a dietary supplement, N-acetyl-L-cysteine (NAC), to treat patients...” NCT06727422 ↗ “N-acetyl cysteine (NAC) infusion 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg...” NCT05370729 ↗ “N-acetylcysteine (NAC), a thiol compound with antioxidant and vasodilatory properties, reduces oxygen free radical production, decreases pump-related ischemia-reperfusion...” NCT01251029 ↗ “N-acetyl cysteine (NAC) has a well-established safety profile, its remarkable antioxidant and anti-inflammatory capacity is the biochemical basis used to treat several diseases...” NCT07229456 ↗ “In this study the investigators will examine whether there is any benefit to using oral N-acetylcysteine (NAC) as an adjunctive treatment for mild to moderate CTS in addition...” NCT04460521 ↗ “BACKGROUND: N-acetylcysteine (NAC) or sodium bicarbonate (NaHCO3), singly or combined, inconsistently prevent patients exposed to radiographic contrast media from developing...” PMID 25254489 ↗ Sep 2014 “acetaminophen (APAP), N-acetylcysteine (NAC) and APAP in combination with NAC will inhibit lipid peroxidation in aneurysmal subarachnoid hemorrhage (aSAH), utilizing F2-IsoPs...” NCT00585559 ↗ “This study evaluated the efficacy, safety, and cost-effectiveness of oral N-acetylcysteine (NAC) in preventing AmB-d nephrotoxicity and promoting renal recovery in Egyptian...” PMID 40342610 ↗ May 2025 “Acetylcysteine group (NAC+S) , aside with the saline, patients will be given orally Acetylcysteine at a dose of 600 mg twice daily, on the day before and on the day of...” NCT01564303 ↗ “more potent, and better-targeted antioxidants, such as N-acetylcysteine (NAC) and Polyunsaturated Fatty Acids(PUFA), will be successful in preventing birth defects in the...” NCT03056014 ↗ “Participants will receive 2.4 grams of oral NAC or similar-appearing placebo during the first visit, and then will cross over to the alternative treatment (NAC or placebo) for...” NCT01037465 ↗ “N-acetylcysteine (NAC) is a medication that is used to treat paracetamol (acetaminophen) overdose, and to loosen thick mucus in individuals with cystic fibrosis or chronic...” NCT04155632 ↗ “N-acetyl cysteine (NAC), an antioxidant drug with anti-inflammatory properties can inhibit oxidative stress as well as inflammatory intermediates, suggesting that it could aid...” NCT06252441 ↗ “The aim of the present study was to assess the impact of N-acetylcysteine (NAC), a potent antioxidant, on endothelial function, B-type natriuretic peptide (BNP) and renal...” PMID 23219310 ↗ Dec 2012 “Anti-oxidants such as N-acetylcysteine (NAc), Vitamin C (ascorbic acid) (VitC) and Vitamin E (alpha-tocopherol) (VitE) are potent FRS 'scavengers', which means they could be...” NCT02629536 ↗ “To investigate the efficacy of N-acetylcysteine (NAC) for decreasing elevated oxidative stress and increasing physical endurance in individuals with ryanodine receptor...” PMID 31941795 ↗ Jan 2020 “N-acetyl cysteine (NAC) is a potential pharmacotherapy for alcohol use disorder (AUD), but it is not known whether it modulates neural activation to alcohol cues or intrinsic...” PMID 39102049 ↗ Aug 2024 “To investigate the role of the antioxidant N-acetylcysteine (NAC) in preventing renal injury in angioplasty, we randomized 352 consecutive patients undergoing primary...” NCT00237614 ↗ “N-acetylcysteine (NAC) is a thiolic amino acid that has been reported to scavenge free radicals, replenish reduced glutathione (GSH), prevent its depletion, and inhibit lipid...” NCT06297369 ↗ “Participants who are randomized to the intervention arm will receive N-Acetyl-L-Cysteine (Free-Form/NAC) 900mg two times a day for 8 weeks after the initiation of the first...” NCT04987775 ↗ “BACKGROUND: Although high-dose N-acetylcysteine (NAC) has been suggested to reduce COPD exacerbations, it is unclear which category of patients with COPD would benefit most...” PMID 24833327 ↗ Sep 2014 “Human embryos will be cultured in media that contains 3 antioxidants (Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)) that can be found in the in...” NCT02971878 ↗ “Patients received supplementation to CC with NAC 1200 mg/day orally (N-acetyl cysteine, Sedico, Cairo, ARE) sachets 200 mg each, as two sachets thrice daily from day 1 to day...” NCT02493933 ↗ “This Phase IIB proof-of-concept study would examine the effects of an investigational product called N-acetylcysteine (NAC) on the basic processes that cause inflammation in CF...” NCT00809094 ↗ “The aim of the present study was to investigate the pathophysiology responsible for the different consequences of HBOT and to evaluate the effect of N-acetylcysteine (NAC) on...” NCT00463671 ↗ “BACKGROUND: Our goal was to determine whether N-acetylcysteine (NAC) administered to the tumescent solution can reduce oxidative stress and increase autologous fat graft (AFG)...” PMID 32424535 ↗ May 2020 “We aim to investigate the efficacy of N-acetylcysteine (NAC) to attenuate acute renal dysfunction in patients with rheumatic valvular heart disease undergoing single valve replacement.” NCT01704482 ↗ “N-acetylcysteine (NAC) has been shown to improve negative symptoms of schizophrenia, however, results from trials of other compounds targeting NMDA neurotransmission have been mixed.” PMID 39144112 ↗ Feb 2024 “Pharmacokinetic data suggests that the intravenous form of n-acetylcysteine (NAC) may be more effective than the oral formulation in preventing contrast induced nephropathy (CIN).” PMID 21542122 ↗ Nov 2011 “This study will examine the effect of N-Acetylcysteine (NAC), an over-the-counter antioxidant supplement, on brains of youth (ages 15-19) using magnetic resonance imaging (MRI).” NCT03238300 ↗ “The purpose of this study is to evaluate the efficacy of N-acetylcysteine (NAC) in preventing cisplatin-induced ototoxicity in patients receiving cisplatin-based chemotherapy.” NCT07364747 ↗ “The goal of this clinical trial is to evaluate if N-acetylcysteine (NAC) works to prevent post-tuberculosis lung disease (PTLD) in patients with severe pulmonary impairment.” NCT06909799 ↗ “The aim of the study was to investigate whether a donor pretreatment with N-acetylcysteine (NAC) reduces the incidence of DGF in adult human kidney transplant recipients.” PMID 25250647 ↗ Apr 2015 “N-acetylcysteine (NAC) is a known potent antioxidant and has been used experimentally in a number of medical conditions in humans for its protective antioxidant effects.” NCT00188773 ↗ “Evaluate the effectiveness of the administration produced antioxidant N-acetylcysteine (NAC), decreasing the incidence of primary graft dysfunction and primary failure.” NCT01866644 ↗ “OBJECTIVE: To examine the efficacy of N-acetylcysteine (NAC) for the treatment of pediatric trichotillomania (TTM) in a double-blind, placebo-controlled, add-on study.” PMID 23452680 ↗ Mar 2013 “Animal studies have shown that INH-RIF-induced oxidative injury can be prevented by supporting the cellular antioxidant defense mechanism by N-acetylcysteine (NAC).” NCT02889757 ↗ “At a tertiary hospital 110 cardiac surgical patients were randomly allocated to peri-operative infusion of NAC (300 mg/kg over 24 h, N = 30) or placebo (N = 80).” PMID 18202091 ↗ Jan 2008 “The purpose of this study is to investigate the efficacy of N-acetylcysteine (NAC) for smoking cessation in a double blind, randomized, placebo-controlled trial.” NCT02124525 ↗ “N-acetylcysteine (NAC) has the ability to replenish intracellular glutathione levels and neutralize ROS makes it promising as adjunct therapy in neonatal sepsis.” NCT07380347 ↗ “The aim of the study is to evaluate the effect of N-acetyl cysteine (NAC) on pregnancy outcome in women undergoing cervical cerclage for cervical insufficiency.” NCT00787813 ↗ “Each eligible Acute Liver Failure patient will be given N-acetylcysteine (NAC), beginning at a dose of 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour” NCT00896025 ↗ “The goal of the proposed study is to evaluate the efficacy and safety of N-Acetyl Cysteine (NAC) in combination with naltrexone in methamphetamine dependence.” NCT00332605 ↗ “A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Multiple Intravenous Doses of N-acetylcysteine (NAC) in Chinese Healthy Volunteers” NCT03881163 ↗ “The objective of this 12-week open-label flexible-dose study was to preliminarily assess the effectiveness of N-acetylcysteine (NAC) in bulimia nervosa (BN).” PMID 23265409 ↗ Nov 2012 “A recent bovine model examined the injection of N-acetylcysteine (NAC) after an intra-articular knee fracture and its effect on the cartilage cell viability.” NCT03652753 ↗ “The aim of the current study was to assess the efficacy of N-acetylcysteine solution (NAC) for relieving symptoms caused by Lugol's iodine chromoendoscopy.” PMID 34371004 ↗ Aug 2021 “N-acetyl cysteine (NAC) is a neuroprotective agent that improved general symptoms, cognitive impairment and negative symptoms in some but not all studies” PMID 29588126 ↗ Mar 2018 “The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom).” NCT03121222 ↗ “Supplementation of N-acetylcysteine (NAC) to ongoing antidepressant therapy may positively influence outcome of depression treatment in these patients.” PMID 30176835 ↗ Sep 2018 “Patients will be randomized to receive N Acetylcysteine (NAC) (four 600 mg capsules given as 2 capsules in the morning and 2 capsules in the evening).” NCT03306979 ↗ “Group A - patients receiving N-acetylcysteine (NAC) 600 mg before performing ERCP and indomethacin suppository 50 mg before and after performing ERCP” NCT03708458 ↗ “A Phase 1 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa” NCT03999021 ↗ “Simethicone and N-acetylcysteine (NAC) are commonly used to improve mucosal visibility, but the optimal timing of administration remains uncertain.” PMID 41960652 ↗ Apr 2026 “Therefore, this study assessed the efficacy and tolerability of N-acetylcysteine (NAC), in children and adolescents with bipolar spectrum disorder.” PMID 35505312 ↗ May 2022 “Recent findings have suggested that N-acetylcysteine (NAC) substantially reduces cocaine drug-seeking behavior in formerly cocaine dependent rats.” NCT00136825 ↗ “This is a pilot study investigating the effect of an antioxidant, N-Acetyl-L-Cysteine (NAC), on inflammation and oxidative stress in sarcoidosis.” NCT01587001 ↗ “N-acetylcysteine (NAC) is an amino acid derivative, is a health supplement, and has neuroprotective effects that target the glutamatergic system.” NCT04904952 ↗ “N-acetyl cysteine (NAC) is an antioxidant well-studied in the perioperative period; it is very safe, relatively inexpensive and widely available.” NCT04732000 ↗ “N-acetylcysteine (NAC) is an antioxidant commonly used in the treatment of acetaminophen overdose, and has well documented mucolytic properties.” NCT00956748 ↗ “Group 1 received vitamin C (Vit C), Group 2 vitamin E (Vit E), Group 3 n-acetylcysteine (NAC), Group 4 melatonin (MT) and group 5 no treatment.” PMID 37174730 ↗ May 2023 “N-Acetylcysteine (NAC) is a thiol-containing antioxidant, which not only acts as a precursor of glutathione but also as a direct antioxidant .” NCT06019520 ↗ “Previous studies have demonstrated the potential beneficial effect of N-acetylcysteine (NAC) in chronic obstructive pulmonary disease (COPD).” PMID 24293993 ↗ Nov 2013 “N-Acetylcysteine (NAC) has been explored for psychiatric disorders for some time given its antioxidant and anti-inflammatory properties.” PMID 29619634 ↗ Apr 2018 “This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis.” NCT03720483 ↗ “N-acetylcysteine (NAC) acts as an antioxidant both directly as a glutathione substitute and indirectly as a precursor for glutathione.” NCT07080190 ↗ “This study is designed to improve knowledge regarding the initial effectiveness of N-acetylcysteine (NAC) on cold and cough symptoms.” NCT02379637 ↗ “treatment with oral N-acetylcysteine (NAC), a widely available dietary supplement, was associated with reduction in NSSI frequency.” PMID 34036177 ↗ Apr 2021 “600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.” NCT01394510 ↗ “Participants were randomly allocated to receive 4 doses of oral NAC (each 1,200 mg) or placebo, administered at 12-hour intervals.” PMID 20541301 ↗ Jun 2010 “N-Acetylcysteine (NAC), a potent anti-oxidant, may prevent IH by improving tissue oxygen delivery and improving hepatic hypoxia.” PMID 32048131 ↗ Feb 2020 “N-acetyl-cysteine (NAC), a glutathione precursor, was administered to patients in a randomized, double-blind, crossover protocol” PMID 22383949 ↗ Feb 2012 “N-acetylcysteine (NAC), alternatively referred to as N-acetyl-L-cysteine, is an acetylated version of the amino acid L-cysteine” NCT07634991 ↗ “The root canals were irrigated with 3 mL N-acetyl Cysteine (NAC)(200 mg/ml) in N-acetyl Cysteine group in the final irrigation.” NCT06834711 ↗ “N-acetyl cysteine (NAC) is an antioxidant, widely used as mucolytic agent or antidote of acetaminophen overdose hepatotoxicity.” NCT04756622 ↗ “N-acetylcysteine (NAC) 150 mg/kg (Max dose 15,000 mg) through an IV that will run for 60 minutes at the start of the procedure.” NCT06039566 ↗ “Karapinar et al N-acetylcysteine (NAC) has been proposed as a potential alternative therapeutic agent in root canal treatment.” NCT05985759 ↗ “The objective of this study is to determine whether the administration of N-acetylcysteine (NAC) improves oxidative stress.” NCT02505087 ↗ “treatment with oral N-acetylcysteine (NAC) will improve behavior problems often associated with autism spectrum disorders.” NCT00453180 ↗ “N-acetylcysteine (NAC)is a powerful antioxidant shown to protect peritoneal fibrosis in peritoneal dialysis animal model.” NCT01111422 ↗ “The Anti-Anginal Effects of N-Acetylcysteine (NAC) in Patients with Angina and Non-Obstructive Coronary Arteries (ANOCA)” NCT06890507 ↗ “N-acetylcysteine (NAC) is effective at preventing liver injury in most patients when started shortly after the overdose.” PMID 37681263 ↗ Oct 2023 “N-acetylcysteine (NAC) is a molecule used in the treatment and prophylaxis of many diseases related to oxidative stress.” PMID 21551083 ↗ May 2011 “with N-acetylcysteine (NAC), the acetylated precursor of both cysteine and glutathione, a key physiological antioxidant” NCT03596125 ↗ “N-acetylcysteine (NAC) is an FDA-approved drug that has been used in multiple conditions to mitigate oxidative stress.” NCT04643821 ↗ “treatment with N-acetylcysteine (NAC) plus deferoxamine (DFX) decreases the incidence of acute kidney injury (AKI).” PMID 27745551 ↗ Oct 2016 “The Efficacy and Safety of N-acetyl-L-cysteine (NAC) as Adjuvant Therapy in Acute on Chronic Liver Failure (ACLF)” NCT05089981 ↗ “Use of Mucomyst (NAC) to Ameliorate Oxidant Stress in Diabetic Patients as Measurable by Surrogate Serum Markers” NCT00493727 ↗ “The intravenous (IV) N-acetylcysteine (NAC) regimen introduced in the 1970s has continued effectively unchanged.” PMID 23556549 ↗ Apr 2013 “The N-Acetylcysteine (NAC), a derivative of the amino acid cysteine, with mucolytic and antioxidant properties” NCT03556371 ↗ “the over the counter agent, N-acetyl cysteine (NAC), in mitigating the development of pruritus (skin itching)” NCT05287724 ↗ “N-acetylcysteine (NAC) and sodium bicarbonate (SOB) therapies may prevent contrast-induced nephropathy (CIN).” PMID 26301645 ↗ Aug 2015 “This proposed pilot study aims to assess the effects of N-acetylcysteine (NAC) on alcohol use disorder (AUD).” NCT04964843 ↗ “Among the most promising approaches is the over-the-counter antioxidant medication N-acetylcysteine (NAC).” NCT03055377 ↗ “N-Acetylcysteine (NAC) is a natural supplement that acts as an antioxidant and glutamate modulating agent.” NCT01172288 ↗ “It is not known whether addition of N-acetyl cysteine (NAC) to G-CSF could further increase survival time.” PMID 29391265 ↗ Jan 2018 “N-acetylcysteine (NAC) is a cysteine analog and sulfur-containing agent, with strong antioxidant activity” NCT00575419 ↗ “N-Acetylcysteine (NAC) has shown promise as a putative neurotherapeutic for traumatic brain injury (TBI).” PMID 37596428 ↗ Aug 2023 “N-Acetylcysteine (NAC) is an active antioxidant proved to be safe and beneficial in hemodialysis patents” NCT00592618 ↗ “N-Acetylcysteine (NAC) is an active antioxidant proved to be safe and beneficial in hemodialysis patents” NCT00421785 ↗ “N-Acetylcysteine (NAC) is an active antioxidant proved to be safe and beneficial in hemodialysis patents” NCT00507052 ↗ “The participants will then undergo 4 days of 600 mg BID oral N-acetylcysteine (NAC) solution treatment” NCT01905696 ↗ “The administration of antioxidants such as n-acetylcysteine (NAC), vitamin C, melatonin, and vitamin E” NCT04570254 ↗ “This study will look at the effects of a medication, called n-acetylcysteine or NAC, on lung function.” NCT03581084 ↗ “N-acetylcysteine (NAC), a glutathione precursor and potent antioxidant, is known as a liver protector.” NCT06039280 ↗ “N-acetylcysteine (NAC) is commonly prescribed for such patients but with uncertain clinical benefits.” PMID 27143871 ↗ Apr 2016 “Participants will receive N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT) for 8 weeks.” NCT02911285 ↗ “NAC (N-Acetylcysteine Tablets, brand name: Flumucil) has a drug specification of 600 mg per tablet.” NCT06956157 ↗ “Since N-acetyl cysteine (NAC) has been proven to have antioxidant and anti-inflammatory properties” NCT05576428 ↗ “N-acetylcysteine (NAC) mucoadhesive nanoparticles in the form of spray 3 times daily for 6 weeks” NCT07082621 ↗ “intravenous N-acetylcysteine (NAC) for the prevention of postoperative myocardial dysfunction” NCT00374088 ↗ “Topiramate (TPM) + N-Acetyl Cysteine (NAC) in combination versus Topiramate (TPM) + placebo” NCT03120468 ↗ “N-acetylcysteine (NAC) is a strong antioxidant that is approved for acetaminophen overdose.” NCT05537220 ↗ “Effect of N-acetylcysteine (NAC) on Hydrogen Sulfide (H2S) in Chronic Kidney Disease (CKD)” NCT01232257 ↗ “N-acetylcysteine (NAC), on a platform of weekly evidence-based brief alcohol intervention” NCT03707951 ↗ “N-acetylcysteine (NAC) decreases inflammation and could augment perioperative analgesia.” PMID 37877260 ↗ Oct 2023 “N-acetylcysteine (NAC), a sulfhydryl group-containing compound with mucolytic properties” NCT07340944 ↗ “N-acetylcysteine (NAC) is a mucolytic with antioxidant and anti-inflammatory properties” NCT06377410 ↗ “N-acetylcysteine (NAC) may mitigate hepatotoxicity, especially among slow acetylators.” NCT06484530 ↗ “high dose oral N-acetyl cysteine (NAC) as adjuvant therapy on clinical outcome of DPN” PMID 40038825 ↗ Mar 2025 “N-acetylcysteine (NAC) is used in Sjögren's disease (SjD) based on limited evidence.” PMID 39360368 ↗ Sep 2024 “standard of care + minocycline + N-acetylcysteine (NAC) relative to standard of care” NCT04594733 ↗ “N-acetylcysteine (NAC) is an oral or intravenous agent that replenishes glutathione” NCT00187330 ↗ “N-acetylcysteine (NAC) is described as having mucolytic and antioxidant properties.” NCT01599884 ↗ “N-acetylcysteine (NAC) has been widely used as an antioxidant in vivo and in vitro.” NCT04209803 ↗ “Zoenasa Rectal Gel (4.0g mesalamine \[5-ASA\], 1.0g N-acetylcysteine \[NAC\]; 60ml)” NCT01586533 ↗ “N-acetyl cysteine (NAC) 600 mg will be administered orally once daily for 12 weeks.” NCT07157722 ↗ “N-acetylcysteine (NAC) is a drug that is commonly used to treat Tylenol overdoses.” NCT00188630 ↗ “N-acetyl cysteine (NAC) is a drug that is metabolized by the body to form cysteine” NCT00218491 ↗ “NAC is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine.” NCT01878695 ↗ “intracanal medication of NAC with concentration 1 gm/ml in the form of a paste” NCT05666089 ↗ “N-acetylcysteine (NAC) to reduce alcohol use and improve brain injury symptoms” NCT02791945 ↗ “NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)” NCT05371288 ↗ “adjunctive N-acetylcysteine (NAC) may improve the efficacy of triple therapy” PMID 32821287 ↗ Jul 2020 “serine, L-carnitine, N-acetylcysteine (NAC) and nicotinamide riboside (NR).” NCT04330326 ↗ “INTRODUCTION: N -acetylcysteine (NAC) may be neuroprotective by minimizing” PMID 35393384 ↗ Apr 2022 “N-acetylcysteine (NAC) has been used for a long time, mainly as mucolytic.” NCT03423667 ↗ “N-acetyl cysteine (NAC) is a widely used drug in human clinical practices.” NCT07323719 ↗ “N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po, 28 days” NCT01138956 ↗ “N-acetylcysteine (NAC) is an attractive agent for the treatment of AAH.” NCT00962442 ↗ “N-acetylcysteine (NAC) for the Treatment of Acute Exacerbation of COPD” NCT05706402 ↗ “using N-acetylcysteine (NAC), a well-tolerated nutritional supplement” NCT04278898 ↗ “using N-acetylcysteine (NAC), a well-tolerated nutritional supplement” NCT05494398 ↗ “N-acetyl cysteine (NAC) may be reduced complications of endometrioma.” NCT05460858 ↗ “N-acetylcysteine (NAC) is a modified form of the amino acid cysteine” NCT03900988 ↗ “N-acetylcysteine (NAC) may have an interest in the treatment of ICD.” NCT03146130 ↗ “intravenous N-acetylcysteine (NAC) can improve bile flow after KP.” NCT03499249 ↗ “two adjunctive medications, N-acetylcysteine (NAC) and gabapentin” PMID 42236678 ↗ Jun 2026 “percutaneous administration of bromelain + N-acetylcysteine (NAC)” NCT04982146 ↗ “high dose of N-acetylcysteine (NAC) plus preprocedural hydration” PMID 41701447 ↗ Feb 2026 “All patients receive N-Acetylcysteine(NAC) and sodium chloride.” NCT01210456 ↗ “N-acetylcysteine (NAC), a well-tolerated nutritional supplement” NCT05664789 ↗ “N-acetylcysteine (NAC) is the most widely used mucolytic agent” NCT00866866 ↗ “Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.” NCT05798481 ↗ “plus oral N-acetylcysteine (NAC) 1200 mg (600mg twice daily)” NCT03281226 ↗ “further improved with N-acetyl-L-cysteine (NAC) treatment.” PMID 40403956 ↗ May 2025 “pre-procedural oral N-acetylcysteine (NAC) and simethicone” NCT07245095 ↗ “The drug N-acetylcysteine (NAC) can act as an antioxidant.” NCT03104725 ↗ “with a dietary supplement called N-Acetyl Cysteine (NAC).” NCT02794389 ↗ “N-acetylcysteine (NAC) has been of considerable interest.” NCT00808795 ↗ “N-acetyl cysteine (NAC) is synthetic cysteine amino acid” NCT05906498 ↗ “Group A and Group B will receive N-Acetylcysteine (NAC).” NCT05340504 ↗ “with the use of an oxidant drug, N acetyl cysteine (NAC)” NCT01614431 ↗ “inhaled N-Acetylcysteine (NAC) to improve lung function” NCT00996424 ↗ “N-acetylcysteine (NAC), an effective mucolytic agent” NCT07293884 ↗ “Prednisolone for 20 days with NAC (N-Acetylcysteine)” NCT02686385 ↗ “N-acetylcysteine (NAC; 1800 mg / day, for 10 days)” NCT04928495 ↗ “This is the medication N-acetylcysteine (NAC)” NCT01993849 ↗ “N-acetylcysteine (NAC) as an antioxidant and” PMID 31381364 ↗ Aug 2019 “Drug: N-acetyl cysteine (NAC) 10% solution” NCT04440280 ↗ “the GSH precursor N-acetylcysteine (NAC).” PMID 22549432 ↗ Sep 2012 “N-acetyl-cysteine (NAC) : 2400 mg per day” NCT05796401 ↗ “Dexamethasone and N-acetylcysteine (NAC)” NCT06811675 ↗ “N-acetyl cysteine (NAC) is a drug” NCT00975689 ↗ “N-Acetylcysteine (NAC) Treatment” NCT07279610 ↗ “N-Acetylcysteine (NAC) Treatment” NCT02966873 ↗ “N-Acetylcysteine (NAC) Treatment” NCT06956482 ↗ “N-acetylcysteine (NAC) treatment” NCT04542161 ↗ “N-Acetylcysteine (NAC) Treatment” NCT07117630 ↗ “N-Acetylcysteine (NAC) Treatment” NCT07273071 ↗ “Drug: N-acetyl cysteine (NAC)” NCT02481609 ↗ “N-acetylcysteine (NAC) 600 mg” NCT03843541 ↗ “Drug: N-Acetyl Cysteine (NAC)” NCT07301294 ↗ “Drug: N-Acetyl Cysteine (NAC)” NCT02054949 ↗ “Drug: N-Acetylcysteine (NAC)” NCT01555970 ↗ “Drug: N-acetylcysteine (NAC)” NCT07156786 ↗ “Oral N-acetylcysteine (NAC)” NCT01800526 ↗ “Drug: Acetylcysteine (NAC)” NCT01223326 ↗ “NAC 600 mg oral once daily” NCT01187108 ↗ “N-acetyl-L-cysteine (NAC)” NCT03391856 ↗ “IV N-acetylcysteine (NAC)” NCT02182167 ↗ “N-acetylcysteine ("NAC")” NCT02583672 ↗ “N-acetyl cysteine (NAC)” NCT03730064 ↗ “N-acetyl-cysteine (NAC)” NCT00822263 ↗ “N-Acetyl Cysteine (NAC)” NCT07323446 ↗ “N-Acetyl Cysteine (NAC)” NCT03063021 ↗ “N-acetylcysteine (NAC)” NCT04013555 ↗ “N-acetylcysteine (NAC)” NCT03757585 ↗ “N-acetylcysteine (NAC)” NCT03636932 ↗ “N-acetylcysteine (NAC)” NCT00428883 ↗ “N-acetylcysteine (NAC)” NCT03911414 ↗ “N-acetylcysteine (NAC)” NCT00650091 ↗ “N-acetylcysteine (NAC)” NCT06482034 ↗ “N-acetylcysteine (NAC)” NCT02269540 ↗ “N-acetylcysteine (NAC)” NCT00004467 ↗ “N-Acetylcysteine (NAC)” NCT07227649 ↗ “N-Acetylcysteine (NAC)” NCT02723162 ↗ “N-acetylcysteine (NAC)” NCT00552786 ↗ “N-acetylcysteine (NAC)” NCT04044131 ↗ “N-Acetylcysteine (NAC)” NCT00780962 ↗ “Drug: NAC” NCT01241513 ↗ “Drug: NAC” NCT01878344 ↗ “NAC” NCT00483314 ↗ |
| Known as | NAC: n-acetylcysteine; Mucomyst | “NAC: n-acetylcysteine; Mucomyst” NCT01137591 ↗ |
| Known as | RK-0202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00230191 ↗ |
| Known as | Siran | “Siran (N-acetylcysteine)” NCT01251029 ↗ |
| Known as | •Chemical Name: Cysteine, N-acetyl-, L | “•Chemical Name: Cysteine, N-acetyl-, L” NCT04481048 ↗ |
| Known as | •Commercial Name(s): Acetin; Acetadote, Acetylcysteine; Airbron; Broncholysin; Fluimucetin; Fluimucil; Inspir; Mucomyst; Mucosolvin; NAC; Parvolex; Respaire | “•Commercial Name(s): Acetin; Acetadote, Acetylcysteine; Airbron; Broncholysin; Fluimucetin; Fluimucil; Inspir; Mucomyst; Mucosolvin; NAC; Parvolex; Respaire” NCT04481048 ↗ |
| Known as | •Synonym:L-alpha-acetamido-beta-mercaptopropionic acid; Mercapturic acid; N-Acetyl-3-mercaptoalanine; N-Acetylcysteine | “•Synonym:L-alpha-acetamido-beta-mercaptopropionic acid; Mercapturic acid; N-Acetyl-3-mercaptoalanine; N-Acetylcysteine” NCT04481048 ↗ |
| Action | Inhibit | “acetylcysteine has been demonstrated to inhibit the production of ox-LDL by ROS.” NCT00247507 ↗ |
| Modality | Small molecule | “It is an acetylated form of amino acid L-cysteine, and is an excellent source of sulfhydryl groups.” NCT00493610 ↗ |
| Route | Intravenous | “acetylcysteine IV over 20 hours” NCT00003346 ↗ |
| Target | MTOR | “profoundly reduced mTOR activity” PMID 22549432 ↗ Sep 2012 |